Reuters - Roche cut its offer for Genentech Inc, launching a hostile bid which dashed investor hopes of a sweetened offer for the 44 percent of the U.S. biotech group its does not already own.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
